Why Johnson & Johnson Rallied Today

Key PointsJohnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, marking J&Js re-entry into the neuroscience field. The stock is still not expensive even after todays surge. 10 stocks we like better than Johnson & Johnson › Shares of Johnson & Johnson (NYSE: JNJ) rallied 6.1% on Wednesday as of 1:18 p.m. ET. The pharmaceutical and medical equipment giant reported earnings today, which not only beat expectations, but also saw man...

2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government

In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poors) downgraded the long-term credit outlook of the United States from its highest designation of AAA to AA+, citing budgetary issues. Fitch once again downgraded U.S. credit in 2023 and Moodys recently suggested its contemplating a similar move. Debt and other fiscal issues only worsened in recent years and the 2024 fiscal deficit ballooned to over $1.8 trillion. High credit ratings are...

J&J’s Top Rating at Risk Because of Intra-Cellular Deal

Johnson & Johnson, one of the last US companies with top credit ratings, is at risk of losing its AAA grade from S&P Global Ratings after the maker of drugs and medical devices said it was acquiring Intra-Cellular Therapies Inc.

These Stocks Are Moving the Most Today: Nvidia, Tesla, Moderna, Intra-Cellular Therapies, D-Wave Quantum, Edison, U.S. Steel, and More

J&J to buy Intra-Cellular Therapies for $14.6 billion

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.

Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies

Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal...

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports By Investing.com

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports

J&J Is in Talks to Buy $10 Billion Biotech Intra-Cellular

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said.

Intra-Cellular Therapies: Parkinsons Disease Drug Expansion Could Be The Next Huge Move

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Companys financial results for the quarter ended September 30, 2024.

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Intra-Cellular Therapies: Downgrade

Zürich (www.aktiencheck.de) - Rating-Update: Die Analysten der UBS stufen die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I, NASDAQ Ticker-Symbol: ITCI) von "buy" auf "neutral" herab. Das Kursziel werde von 85,00 auf 83,00 USD reduziert. (Update vom 25.06.2024) Bitte beachten Sie auch Informationen zur Offenlegungspflicht bei Interessenskonflikten im Sinne der Richtlinie 2014/57/EU und entsprechender Verordnungen der EU unter folgendem Link. [mehr]

Intra-Cellular Therapies: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Mizuho Securities USA bewerten die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I, NASDAQ Ticker-Symbol: ITCI) unverändert mit "buy". Das Kursziel werde von 96,00 auf 100,00 USD gesteigert. [mehr]

Intra-Cellular Therapies: Klares Upside-Potenzial - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Intra-Cellular Therapies-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Intra-Cellular Therapies Inc (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I, NASDAQ Ticker-Symbol: ITCI) unter die Lupe. [mehr]

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.This condition affects more than 6.9 million people in the US alone; it’s also ...

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.

Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA.